icon_loop icon_cart icon_arrow-down icon_pick-winners icon_make-better-decisions icon_gofaster-gosmarter icon_equio icon_custom-research icon_conquer-the-wild icon_be-anonymous-and-secure icon_analyst-reports icon_access-realtime-data icon_youtube icon_twitter icon_linkedin icon_facebook

Illinois Legalizes Industrial Hemp

By Larry Mishkin, Hoban Law Group, Litigation Practice Group Counsel Last month, Illinois Gov. Bruce Rauner signed into law Senate Bill 2298, the Illinois Industrial Hemp Act, which became effective immediately. The act allows Illinois farmers, in conjunction with a university or other recognized research group, to cultivate industrial hemp for research and commercial purposes. […]
Read more

Cannabis Research Efforts Progressing Despite Federal Tax and Banking Regulations

By Michael Harlow and Craig Golding Partners at CohnReznick There are some unique challenges to conducting research in the United States on the medical applications of cannabis. Cannabis’ federal Schedule I classification presents several obstacles for cannabis industry operators and businesses, even for those located in states where medical and recreational use is legal. Strict [...]
Read more

States Challenged to Optimize Cannabis Tax Revenues

Some reinventing the cannabis tax-reform wheel as they go along By Tracy Curley, Partner at Cohnreznick The legal status of cannabis presents a challenge toward advancements in quality assurance and medical research. Currently, the Controlled Substance Act carries no distinction between the medical and recreational uses of cannabis, which is classified as a Schedule I […]
Read more

States Challenged to Optimize Cannabis Tax Revenues

Some reinventing the cannabis tax-reform wheel as they go along By Bob Moss, Principal, National Director of Governmental Affairs & Eddie Delgado, CMI, Cohn Reznick For the states with cannabis initiatives on the ballot this fall, there is a fine line between passing legislation and being prepared to implement the new law. With time and more […]
Read more

CBD Offers Both Opportunities and Obstacles Yet to Be Determined

By J.J. McCoy, Senior Managing Editor for New Frontier Data As California works out the kinks in its new if long-anticipated adult-use market, and Canada prepares to roll out its nationwide industry in October, the overall cannabis industry in North America is already a multi-billion-dollar enterprise. Yet growth opportunities abound, and activity at the ground and […]
Read more

Caribbean Island Nations Getting Onboard with Decriminalization

By J.J. McCoy, Senior Managing Editor for New Frontier Data After a meeting this month by heads of state among the Caribbean Community (CARICOM) including Bahamas, Barbados, Haiti, Jamaica, and 15 other neighboring island nations, the group came to some consensus toward legalizing and regulating cannabis. The officials agreed to “review marijuana’s current status with a […]
Read more

Despite Recognition of Injustice, Arrest Rates for Cannabis Remain Unequal

By J.J. McCoy, Senior Managing Editor for New Frontier Data New research from New Frontier Data finds that cannabis arrests account for 41.6% of all drug-related arrests, with 15.7 million Americans having been arrested for cannabis (either possession, sales, or manufacturing) from 1997-2016. Yet application of unequal justice finds that black or Hispanic suspects are arrested […]
Read more

The DEA Is Rescheduling Epidiolex, But Not (Yet) Cannabis or CBD

By J.J. McCoy, Senior Managing Editor for New Frontier Data The U.S. Food and Drug Administration (FDA) last week made history: By giving approval for U.K.-based GW Pharmaceuticals’ application to market Epidiolex (to medically treat severe forms of epilepsy), it marked the FDA’s groundbreaking admission that cannabis has medical value. That said, despite some companies trying […]
Read more

Is Talk About the STATES Act for Real? Or Just More Static?

By J.J. McCoy, Senior Managing Editor for New Frontier Data Judging by a flurry of anxious headlines this month, the U.S. Congress (with President Trump’s “probable” blessing) may well be on the verge of ending 81 years of prohibition of marijuana. Unless of course it’s not. Welcome to America, 2018. What is known for certain is […]
Read more

Five Key Risks and Exposures of Canadian Licensed Producers (LPs): What Should Investors Be Worried About?

By Yona Torres, Editor, New Frontier Data As exiting opportunities arise from the Canadian cannabis market, investors should be aware of five key risks and exposures challenging the country’s licensed producers (LPs). Overproduction: There are currently 109 Canadian license producers (LPs) of medical cannabis with production capabilities that significantly outweigh domestic demand. To remain [...]
Read more